Durvalumab is a selective, high-affinity human immunoglobulin monoclonal antibody in a class called check point inhibitors, that blocks PD-L1 on tumour cells. Despite clinical success in increasing progression-free survival rates in patients with stage III non-small-cell lung cancer, durvalumab has been associated with immune-related side effects such as pneumonitis and colitis. We present a case of an 84-year-old woman with acral vasculitis presenting as blue toe syndrome, associated with prolonged use of durvalumab. After 1 year of fortnightly durvalumab therapy postchemoradiation therapy, the patient came in with a left blue big toe, and later developed bilateral livedo racemosa. The diagnosis of durvalumab-associated vasculitis was made and treatment with prednisolone was started with clinical improvement.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Gupta, S., Xu, D., Hadfield, J., & Prentice, D. (2020). Durvalumab-associated vasculitis presenting as “the blue toe syndrome.” BMJ Case Reports, 13(11). https://doi.org/10.1136/bcr-2020-235886